Ophthalmic care company NuSight Medical has introduced a new medical device called the NuLids System to treat dry eyes.

Unveiled at the American Optometric Association meeting in Denver, NuLids is said to improve dry eye conditions by gently stimulating and rejuvenating the Meibomian glands in the eye.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

NuSight Medical president and CEO Rob Foster said: “Patients benefit from improved tear film stability, comfort, and lubrication that combat dry eye. Doctors gain an important therapy while helping to build their practice.

“The company stated that under the NuLids I and NuLids II clinical studies, nearly 95% of patients surveyed following a 30-day trial were said to be satisfied or very satisfied with the treatment.”

“And, because NuLids is sold only through licensed eye care practitioners, doctors are in control of the therapy while patients perform the treatment at home, improving practice efficiency.”

NuSight Medical founder and chairman John Olkowski said that nearly 86% of dry eye patients’ Meibomian gland function are damaged leading to unstable tear film and its premature breakdown.

The NuLids facilitates the production and flow of meibum at the gland reducing signs of dry eye.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

At a clinical study, the NuLids System bettered Tear Breakup Time by 65%, while Meibomian Glands Yielding Liquid Secretions improved by 81%.

Most of the patients in the study also reported significant improvement in their dry eye conditions following two weeks of daily usage.

Taking around one minute per day, the NuLids process can be carried out with the in-office procedures performed by eye doctors.

NuSight claimed that the NuLids system is convenient to use without any known side effects.

The company also stated that under the NuLids I and NuLids II clinical studies, nearly 95% of patients surveyed following a 30-day trial were said to be satisfied or very satisfied with the treatment.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact